Search Grant Opportunities

DoD Tuberous Sclerosis Complex, Exploration-Hypothesis Development Award

ID: HT942524TSCRPEHDA • Type: Posted
Opportunity Assistant

Hello! Please let me know your questions about this opportunity. I will answer based on the available opportunity documents.

Sign in to upload a capability statement or catalogue for your company

Some suggestions:
Please summarize the work to be completed under this opportunity
Who is eligible to apply for this grant?
I'd like to anonymously submit a question to the procurement officer(s)

Description

The EHDA supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the TSC research field. The studies supported by this award mechanism are expected to generate preliminary data for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on a strong scientific rationale and study design. Applications should demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis.

The following are important aspects of the EHDA:

Innovation: Innovative research may introduce a new paradigm, challenge existing paradigms, examine existing problems from new perspectives, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative and is not consistent with the intent of the award mechanism.

Although not all-inclusive, the following examples are ways in which the proposed research project may be innovative:

Explores a novel idea and/or research question in TSC research and/or patient care.

Uses or develops novel methods or technologies to address a question in TSC research and/or patient care.

Applies or adapts existing methods or technologies for novel TSC research or clinical purposes that differ fundamentally from those originally intended.

Background
The EHDA supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the TSC research field. The studies supported by this award mechanism are expected to generate preliminary data for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on a strong scientific rationale and study design.

Grant Details
The FY24 TSCRP Exploration-Hypothesis Development Award (EHDA) encourages applications in mechanistic studies, animal model development, biomarkers, therapeutics, and patient-centered studies that address specific focus areas related to Tuberous Sclerosis Complex (TSC).
The award mechanism aims to fund innovative research that introduces new paradigms or challenges existing paradigms in TSC research and patient care. It also encourages the development and testing of emerging technologies to improve outcomes in TSC.
Clinical trials are not allowed under this funding opportunity.

Eligibility Requirements
Extramural and Intramural organizations are eligible to apply, including foreign or domestic organizations, for-profit and non-profit organizations, and public entities.
Independent investigators and postdoctoral fellows (or equivalent) are eligible to be named as the Principal Investigator (PI) on applications.

Period of Performance
Awards supported with FY24 funds will be made no later than September 30, 2025.
The period of performance for an FY24 TSCRP EHDA should not exceed $150,000.
Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds.

Grant Value
$1.2M is expected to be allotted to fund approximately five TSCRP Exploration-Hypothesis Development Award applications.

Place of Performance
The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public.
Show All

Overview

Agency
U.S. Army Medical Research Acquisition Activity (USAMRAA) [DoD - USA - MEDCOM - MRDC]
Category of Funding
Science and Technology and other Research and Development
Funding Instruments
Grant
Grant Program (CFDA)
12.420 - Military Medical Research and Development
Grant Category
Discretionary
Cost Sharing / Matching Requirement
False
Source
Grants.gov
On 4/19/24 U.S. Army Medical Research Acquisition Activity posted grant opportunity HT942524TSCRPEHDA for DoD Tuberous Sclerosis Complex, Exploration-Hypothesis Development Award with funding of $1.2 million. The grant will be issued under grant program 12.420 Military Medical Research and Development. It is expected that 5 total grants will be made.

Timing

Posted Date
April 19, 2024, 12:00 a.m. EDT
Closing Date
Aug. 1, 2024, 12:00 a.m. EDT Past Due
Last Updated
April 19, 2024, 2:45 p.m. EDT
Version
1
Archive Date
Aug. 31, 2024

Eligibility

Eligible Applicants
Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Award Sizing

Ceiling
Not Listed
Floor
Not Listed
Estimated Program Funding
$1,200,000
Estimated Number of Grants
5

Contacts

Contact
Jamie Shortall Grant Officer
Contact Email
help@ebrap.org   Profile
Email Description
CDMRP Help Desk
Contact Phone
(301) 619-2393

Documents

Posted documents for HT942524TSCRPEHDA

Grant Awards

Grants awarded through HT942524TSCRPEHDA

Incumbent or Similar Grants

Grants similar to HT942524TSCRPEHDA

Similar Active Opportunities

Open grant opportunities similar to HT942524TSCRPEHDA

Experts for DoD Tuberous Sclerosis Complex, Exploration-Hypothesis Development Award

Recommended subject matter experts available for hire